Irofulven companion diagnostic - Oncology Venture

Drug Profile

Irofulven companion diagnostic - Oncology Venture

Alternative Names: Irofulven Drug Response Predictor (DRP™) - Oncology Venture; Oncology companion diagnostic

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncology Venture
  • Developer Eisai Inc; Oncology Venture
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer

Most Recent Events

  • 29 May 2017 Oncology Venture has patents pending for Irofulven companion diagnostic - Oncology Venture in USA
  • 29 May 2017 Phase-II clinical trials in Cancer (Diagnosis) (unspecified route) before May 2017
  • 24 Mar 2017 Preclinical trials in Cancer in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top